Clinic
Texas Health Huguley, INC.
Texas Health Huguley, INC. was paid $8.51M by Medicaid between Jul 2020 and Dec 2024, across 117 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoTEXAS HEALTH HUGULEY, INC.
BURLESON, TX 76028
BURLESON, TX 76028
33aNPI1033120423assigned 08/10/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$8.51M
24GClaims157,632
24DCodes billed117
24AFirst – last monthJul 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#52 of 320
Median peer was paid$205K
This provider vs. median42×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,157 | $229K | |
| 2021 | 37,788 | $1.44M | |
| 2022 | 46,559 | $2.02M | |
| 2023 | 45,778 | $3.38M | |
| 2024incomplete | 23,350 | $1.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 10,362 | 9,616 | $2.06M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 17% | 421 | 412 | $1.41M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 9.9% | 1,344 | 913 | $844K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.2% | 13,463 | 12,819 | $702K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 5.5% | 4,283 | 4,085 | $471K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 4.4% | 477 | 448 | $371K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 3.5% | 1,832 | 1,765 | $297K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.7% | 1,428 | 1,366 | $230K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 1,828 | 1,629 | $209K |
| 42830 | 2.2% | 138 | 137 | $191K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 1,217 | 1,177 | $151K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 4,000 | 3,808 | $136K |
105 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 3,998 | $136K |
| 80053 | Comprehensive metabolic panel | 1.5% | 11,071 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 1,075 | $121K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 14,521 | $100K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 143 | $71K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,600 | $70K |
| 86780 | <1% | 3,762 | $58K | |
| 86850 | <1% | 2,182 | $56K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,046 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 833 | $41K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,933 | $38K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,861 | $33K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 994 | $30K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 936 | $28K |
| 86762 | <1% | 1,620 | $28K | |
| 42821 | <1% | 12 | $27K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 525 | $25K |
| 81001 | <1% | 6,610 | $23K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 910 | $22K |
| 87340 | <1% | 1,690 | $20K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 177 | $20K |
| 85027 | <1% | 2,546 | $19K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,448 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,425 | $18K |
| 80050 | General health panel | <1% | 84 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 455 | $13K |
| 87081 | <1% | 1,684 | $13K | |
| 86803 | <1% | 719 | $12K | |
| 82950 | <1% | 1,844 | $11K | |
| 84702 | <1% | 842 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 169 | $10K |
| 84484 | <1% | 1,853 | $9K | |
| 81513 | <1% | 68 | $9K | |
| 81025 | <1% | 1,171 | $9K | |
| 86900 | <1% | 2,288 | $8K | |
| 90715 | <1% | 374 | $8K | |
| 86901 | <1% | 2,290 | $8K | |
| 59025 | Fetal non-stress test | <1% | 201 | $8K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 241 | $6K |
| 80061 | Lipid panel | <1% | 1,209 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,128 | $5K |
| 86003 | <1% | 98 | $5K | |
| 84703 | <1% | 833 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 355 | $5K |
| 83880 | <1% | 363 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 324 | $4K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 62 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 26 | $3K |
| 83690 | <1% | 1,137 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 27 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 654 | $3K |
| 87480 | <1% | 170 | $2K | |
| 87660 | <1% | 170 | $2K | |
| 82077 | <1% | 239 | $2K | |
| 84030 | <1% | 415 | $2K | |
| 83735 | <1% | 580 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 919 | $2K |
| 87070 | <1% | 385 | $2K | |
| 87077 | <1% | 559 | $2K | |
| 82947 | <1% | 701 | $2K | |
| 81511 | <1% | 312 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 112 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 273 | $2K |
| 81329 | <1% | 17 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,163 | $1K |
| 87510 | <1% | 102 | $1K | |
| 85610 | <1% | 743 | $1K | |
| 87481 | <1% | 62 | $974.52 | |
| 85730 | <1% | 387 | $918.18 | |
| 82247 | <1% | 121 | $874.55 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 545 | $863.25 |
| 87040 | <1% | 268 | $825.48 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 588 | $810.66 |
| 86787 | <1% | 63 | $763.56 | |
| 87186 | <1% | 304 | $722.85 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 24 | $719.04 |
| 81003 | <1% | 550 | $708.29 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 308 | $705.25 |
| 83605 | <1% | 219 | $688.77 | |
| 83021 | <1% | 34 | $616.39 | |
| 82248 | <1% | 114 | $557.47 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 64 | $521.18 |
| 82607 | <1% | 63 | $459.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 383 | $452.53 |
| 82105 | <1% | 34 | $418.39 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 131 | $325.42 |
| 82746 | <1% | 29 | $269.23 | |
| 82570 | <1% | 126 | $261.87 | |
| 82043 | <1% | 63 | $144.99 | |
| 82951 | <1% | 14 | $118.99 | |
| 86140 | <1% | 76 | $99.15 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 47 | $92.93 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 44 | $87.94 |
| 84146 | <1% | 43 | $87.54 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 72 | $71.14 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 39 | $64.47 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 118 | $56.76 |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,499 | $47.91 |
| 84439 | <1% | 12 | $36.43 | |
| 82952 | <1% | 14 | $36.21 | |
| 87641 | <1% | 14 | $29.48 | |
| 85379 | <1% | 12 | $14.31 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 36 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 26 | $0.00 |
| 96376 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, PENNY (CHIEF EXECUTIVE OFFICER)